hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06297291 id: CLN0984 briefTitle: Global Paradise System US Post Approval Study acronym: US GPS overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-09 date: 2031-07 date: 2024-03-07 date: 2024-03-07 name: ReCor Medical, Inc. class: INDUSTRY briefSummary: The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood pressure with lifestyle changes and medication. This system is comprised of a catheter, cable, balloon, and generator and has received FDA approval in the United States. Information collected in this study will be analyzed to better understand the long-term safety and effectiveness of treatment with the Paradise System for patients with high blood pressure. conditions: Hypertension conditions: Cardiovascular Diseases conditions: Vascular Diseases studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 1000 type: ESTIMATED name: Paradise Ultrasound Renal Denervation Treatment measure: Co-Primary Endpoint #1: Group Mean BP reduction measure: Co-Primary Endpoint #2: Subject Responder measure: Change in mean home systolic/diastolic BP in mmHg measure: Change in mean office systolic/diastolic BP in mmHg measure: Change in home and office pulse pressure measure: Change in the number and/or dosage and/or type of antihypertensive medications taken measure: Change in patient reported outcomes measure: Percentage of patients who are controlled as measured by various cut points of home BP (control to be assessed as both < 130 mmHg systolic and <135 mmHg systolic) office BP (control to also be assessed as <130 mmHg and <140 mmHg systolic) measure: Percentage of patients who demonstrate a reduction in home systolic BP of ≥ 5mmHg, ≥ 10 mmHg and ≥ 15 mmHg measure: Percentage of patients who demonstrate a reduction in office systolic BP of ≥ 5mmHg, ≥ 10 mmHg and ≥ 15 mmHg measure: Change in home and office heart rate sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06297278 id: IRB-23-01-5444 id: R01MH132830 type: NIH link: https://reporter.nih.gov/quickSearch/R01MH132830 briefTitle: Exercise Facilitation of Adolescent Fear Extinction, Frontolimbic Circuitry, and Endocannabinoids acronym: BRAINS overallStatus: RECRUITING date: 2024-05-01 date: 2028-04-30 date: 2028-04-30 date: 2024-03-07 date: 2024-04-23 name: Wayne State University class: OTHER name: National Institute of Mental Health (NIMH) briefSummary: Anxiety disorders commonly begin during adolescence, and are characterized by deficits in the ability to inhibit or extinguish pathological fear. Recent research has provided new understanding of how fear is learned and can be regulated in the adolescent brain, and how the endocannabinoid system shapes these processes; however, these advances have not yet translated into improved therapeutic outcomes for adolescents with anxiety. This study will test whether a behavioral intervention, acute exercise, can help to improve fear regulation by enhancing brain activity and endocannabinoid signaling. This line of research may ultimately lead to more effect treatments for adolescent anxiety, and to new preventive strategies for at-risk youth. conditions: Adolescence studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: NONE count: 174 type: ESTIMATED name: Moderate Intensity Exercise measure: Skin Conductance Responding (SCR) measure: Unconditioned Stimulus (US) Expectancy Ratings measure: Fear extinction neural circuitry: Functional activation and coupling measure: Endocannabinoid (eCB) Concentrations measure: Fear Ratings measure: Approach/Avoidance Behavior measure: Amygdala response during extinction recall sex: ALL minimumAge: 14 Years maximumAge: 17 Years stdAges: CHILD facility: Tolan Park Medical Building status: RECRUITING city: Detroit state: Michigan zip: 48201 country: United States name: MacKenna Shampine role: CONTACT phone: 313-242-7464‬ email: mackenna.shampine@wayne.edu lat: 42.33143 lon: -83.04575 hasResults: False
nctId: NCT06297265 id: 1B-23-2 id: NCI-2023-10828 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: 1B-23-2 type: OTHER domain: USC / Norris Comprehensive Cancer Center id: P30CA014089 type: NIH link: https://reporter.nih.gov/quickSearch/P30CA014089 briefTitle: Manual Lymphatic Drainage Breast Massage in Breast Cancer Patients After Breast Conserving Surgery overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-04-01 date: 2027-04-01 date: 2024-03-07 date: 2024-03-07 name: University of Southern California class: OTHER name: National Cancer Institute (NCI) briefSummary: This phase II trial evaluates manual lymphatic drainage breast massage for reducing treatment-related side effects in women undergoing radiation therapy after breast conserving surgery for breast cancer that has not spread to other parts of the body (localized). Breast conserving surgery can be an effective treatment option for early stage breast cancer, but it can also be associated with side effects including fluid collection in tissues/swelling (lymphedema), pain, reduced quality of life, and poorer body image. Manual lymphatic drainage is a gentle massage technique used to reduce swelling. It may be a safe and effective way to reduce treatment-related side effects in women receiving radiation therapy after surgery for localized breast cancer. conditions: Anatomic Stage 0 Breast Cancer AJCC v8 conditions: Anatomic Stage IA Breast Cancer AJCC v8 conditions: Localized Breast Carcinoma studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 50 type: ESTIMATED name: Lymphedema Management name: Questionnaire Administration name: Adjuvant breast radiation therapy measure: Rate of compliance of MLD breast massage sessions measure: Assess the effect of MLD breast massage breast edema measure: Assess the effect of MLD breast massage on pain measure: Assess the effect of MLD breast massage on functional status measure: Assess the effect of MLD breast massage on quality of life measure: Assess the effect of MLD breast massage on body image sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: USC / Norris Comprehensive Cancer Center city: Los Angeles state: California zip: 90033 country: United States name: Kimberly Arieli, RN role: CONTACT phone: 323-865-0451 email: Kimberly.Arieli@med.usc.edu name: May L. Tao, MD role: PRINCIPAL_INVESTIGATOR lat: 34.05223 lon: -118.24368 hasResults: False
nctId: NCT06297252 id: RECHMPL23_0189 briefTitle: Prevalence of Psychiatric Disorders During Pregnancy at 2nd Trimester Ultrasound: a Feasibility Study in the General Population acronym: GROUP overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-03 date: 2026-09 date: 2024-03-07 date: 2024-03-07 name: University Hospital, Montpellier class: OTHER name: Beziers Hospital briefSummary: Young women represent a population at risk of psychiatric disorders, the first signs of which often appear between the ages of 15 and 25. Psychiatric disorders are a major source of disability and healthcare costs.
nctId: NCT06297239 id: UC001 briefTitle: Argentine Registry of Lp(a) acronym: GAELpa overallStatus: RECRUITING date: 2024-02-01 date: 2026-02-01 date: 2026-02-01 date: 2024-03-07 date: 2024-03-07 name: School of Medicine. National University of Cuyo class: OTHER briefSummary: The Argentine Registry on Lipoprotein(a) (LP(a)), orchestrated by the Argentine Group for LP(a) Study, stands as a pioneering and extensive prospective initiative. This registry systematically collects geolocation data, including patient postal codes, demographic information, and a multifaceted array of health parameters to unravel the intricate associations surrounding LP(a) levels.
The prospective nature of this registry allows for dynamic analyses, fostering a continuous exploration of emerging patterns and trends. By amalgamating geographical, clinical, and genetic data, the Argentine LP(a) Registry emerges as a comprehensive platform poised to unlock novel facets of LP(a) biology and its implications for cardiovascular health. As the dataset matures, it holds the promise of guiding personalized interventions and refining risk stratification strategies, thereby advancing the landscape of preventive cardiovascular care. conditions: Lp(A) conditions: Hypercholesterolemia conditions: Cardiovascular Diseases conditions: Diabete Type 2 conditions: Hypertension studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1000 type: ESTIMATED measure: prevalence of high level of Lp(a) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Universidad Nacional de Cuyo status: RECRUITING city: Mendoza zip: 5500 country: Argentina name: Nicolás F Renna, PhD MD FESC role: CONTACT phone: +5492615714415 email: nicolasfede@gmail.com name: Pablo Corral, MD role: CONTACT lat: -32.89084 lon: -68.82717 hasResults: False
nctId: NCT06297213 id: R-2487-SS-01 briefTitle: R-2487 in Patients With Sjogren's Syndrome (SS) acronym: R-2487-SS-01 overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2026-08-30 date: 2026-08-30 date: 2024-03-07 date: 2024-04-12 name: Rise Therapeutics LLC class: INDUSTRY briefSummary: The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-2487) in patients with Sjogren's Syndrome.
Patients will take an oral dosage of probiotic (R-2487) and physicians will assess and measure their Sjogren's Syndrome. Blood and fecal evaluations of inflammation and assessment of probiotic (R-2487) on fecal level will also be measured. conditions: Sjogren's Syndrome conditions: Sjögren conditions: Sjögren Syndrome, Unspecified studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 36 type: ESTIMATED name: R-2487 measure: Incidence and severity of adverse events and their relationship to R-2487 (probiotic) administration measure: Change in disease activity through Clinical European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ClinESSDAI) measure: Change in Patient reported general health questionnaire Short Form Health Survey-36(SF-36) sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06297200 id: 24-050 briefTitle: Low-Intensity Focused Ultrasound and the Complex Patient overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-10 date: 2025-10 date: 2024-03-07 date: 2024-03-07 name: Virginia Polytechnic Institute and State University class: OTHER name: Salem VA Medical Center name: Washington DC VA Medical Center briefSummary: Studying the effects of Low Intensity Focused Ultrasound (LIFU) on measures of pain, craving, and anxiety in a complex patient population. conditions: Opioid Use Disorder conditions: Chronic Pain conditions: Anxiety Disorder studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE maskingDescription: Sham trials will be utilized within subject. All subjects will receive sham and ultrasound conditions. count: 25 type: ESTIMATED name: Low-Intensity Focused Ultrasound name: Low-Intensity Focused Ultrasound - sham measure: Incidence of Treatment-Emergent Adverse Events via a neurological examination measure: Incidence of Treatment-Emergent Adverse Events via a side effects questionnaire measure: Changes in Heart Rate (HR) measure: Changes in Respiration Rate (RR) measure: Changes in mood via visual analog mood scale (VAMS) measure: Changes in Blood Pressure (BP) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fralin Biomedical Research Institute at VTC city: Roanoke state: Virginia zip: 24016 country: United States name: Jessica Florig, MPH role: CONTACT phone: 540-526-2261 email: jnw@vtc.vt.edu name: Wynn Legon, PhD role: PRINCIPAL_INVESTIGATOR lat: 37.27097 lon: -79.94143 hasResults: False
nctId: NCT06297187 id: C-CUSAWH-001 briefTitle: Cavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health Study overallStatus: ACTIVE_NOT_RECRUITING date: 2024-02-23 date: 2024-07 date: 2024-08 date: 2024-03-07 date: 2024-03-07 name: Integra LifeSciences Corporation class: INDUSTRY briefSummary: The study is a single arm, retrospective, single-center, post market registry.
The purpose of this Registry is to collect data to demonstrate the safety and performance of CUSA® for the treatment of Vulvar Intraepithelial Neoplasia (VIN) and condyloma acuminata. conditions: Vulvar Intraepithelial Neoplasia conditions: Condylomata Acuminata studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 75 type: ESTIMATED name: CUSA (Cavitronic Ultrasonic Surgical Aspirator) measure: Proportion of Subjects with Complete Removal of Vulvar Intraepithelial Neoplasia and condyloma acuminata measure: Primary Site Recurrence sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Center for Cancer and Blood Disorders city: Dallas state: Texas zip: 76014 country: United States lat: 32.78306 lon: -96.80667 hasResults: False
nctId: NCT06297174 id: BE23-035 briefTitle: Bioequivalence Study of Generic Racecadotril 100 mg Capsules Under Fasting Conditions overallStatus: NOT_YET_RECRUITING date: 2024-08-26 date: 2024-09-17 date: 2024-09-20 date: 2024-03-07 date: 2024-03-07 name: Pharma Nueva class: INDUSTRY briefSummary: Objectives:
An open label, randomized, two-treatment, four-period, two-sequence, replicate crossover bioequivalence study in healthy Thai volunteers under fasting conditions with at least 7 days washout period between the administrations of investigational products of each period conditions: Healthy Vollunteer studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 44 type: ESTIMATED name: Racecadotril 100 mg Capsules name: HIDRASEC® measure: Plasma area Under the Curve (AUC(0-36hr)) for Racecadotril measure: Peak Plasma Concentration (Cmax) of Racecadotril sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT hasResults: False
nctId: NCT06297161 id: B1871065 briefTitle: A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML). overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2029-12-31 date: 2029-12-31 date: 2024-03-07 date: 2024-03-07 name: Pfizer class: INDUSTRY briefSummary: The purpose of this study is to look at how safe and effective is bosulif in routine clinical practice.
In this study all treatment and checking of the patients will be done as per the study doctor. The study can be performed in Korean health care centers where bosulif is prescribed to treat CML after the patients have agreed to take part in the study. conditions: Chronic Leukemia Myelogenous studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 600 type: ESTIMATED name: Bosulif measure: Incidence of AEs measure: Hematologic response: CHR, not achieved measure: Cytogenetic response: CCyR, PCyR, mCyR, not achieved measure: Molecular response: EMR, MMR, MR4.0, MR4.5, not achieved measure: Relapse after Bosulif response sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06297148 id: 2023/590816 briefTitle: The HIP Self-management Study acronym: HIPS overallStatus: RECRUITING date: 2024-03-12 date: 2026-07-01 date: 2027-01-01 date: 2024-03-07 date: 2024-03-21 name: Oslo University Hospital class: OTHER name: Oslo Metropolitan University name: Fysiofondet name: University of Oslo briefSummary: The HIPS-study will be an observer blinded, single-centre, parallel-group randomized controlled trial (RCT).
Follow-up will be at 3-, 6- and 12-months. conditions: GTPS - Greater Trochanteric Pain Syndrome conditions: Gluteal Tendinopathy conditions: Trochanteric Bursitis conditions: Lateral Hip Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 110 type: ESTIMATED name: Self-management name: Usual care measure: Victorian Institute of Sport Assessment Gluteal Questionnaire (VISA-G) measure: Numeric rating scale (NRS) measure: Painful sites measure: The Pain Self-Efficacy Questionnaire (PSEQ) measure: EuroQoL-5 dimensions-5 Level (Eq-5D-5L) measure: Hopkins Symptoms checklist-10 (HSCL-10) measure: iMTA Medical Consumption Questionnaire (iMCQ) measure: iMTA Productivity Cost Questionnaire (iPCQ) measure: Expectations related to VISA-G measure: Expectations on numeric rating scale (NRS) measure: Global rating of change (GROC) sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Oslo University Hospital, Ullevål status: RECRUITING city: Oslo zip: 0450 country: Norway name: Marianne Bakke Johnsen, PhD role: CONTACT phone: + 47 92439663 email: m.b.johnsen@medisin.uio.no name: Marianne Bakke Johnsen, PhD role: PRINCIPAL_INVESTIGATOR lat: 59.91273 lon: 10.74609 typeAbbrev: SAP hasProtocol: False hasSap: True hasIcf: False label: Statistical Analysis Plan date: 2024-02-22 uploadDate: 2024-03-07T09:23 filename: SAP_001.pdf size: 1180746 hasResults: False
nctId: NCT06297135 id: HSR-2023-020 briefTitle: A Feasibility Study of a Support Program for Building New Parent-child Behavioral Habits overallStatus: RECRUITING date: 2024-02-01 date: 2025-03-31 date: 2025-03-31 date: 2024-03-07 date: 2024-03-07 name: Okinawa Institute of Science and Technology Graduate University class: OTHER name: Miyazaki International College name: Japan society for the promotion of science briefSummary: This study evaluates the feasibility and preliminary impacts of a new parent support program consisting of a series of educational videos, delivered via a popular texting platform. For this pilot project, the program content is focused on teaching parents strategies to better manage one of the commonly reported challenges children face, a transition to a non-preferred activity. Parents with children demonstrating inattentive, hyperactive and impulsive behavior and experiencing difficulties with daily transition routines are invited to participate in the study. conditions: ADHD studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: Behavioral Parent Training measure: Number of videos viewed measure: Percentage of completed daily ratings measure: Participant satisfaction measure: Parent-rated child's difficulties with daily transitions measure: Parent-rated child's impairment related to transition difficulties measure: Positive parenting measure: Negative parenting measure: Parenting stress measure: ADHD symptoms measure: ODD symptoms sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Okinawa Institute of Science and Technology Graduate University status: RECRUITING city: Onna state: Okinawa zip: 904-0495 country: Japan name: Emi Furukawa, PhD role: CONTACT phone: +81989668814 email: adhd@oist.jp name: Emi Furukawa, PhD role: PRINCIPAL_INVESTIGATOR facility: Miyazaki International College status: RECRUITING city: Miyazaki zip: 889-1605 country: Japan name: Aya Kasai, PhD role: CONTACT phone: +81985855931 email: akasai@sky.miyazaki-mic.ac.jp name: Aya Kasai, PhD role: PRINCIPAL_INVESTIGATOR lat: 31.91667 lon: 131.41667 hasResults: False
nctId: NCT06297122 id: APHP240002 briefTitle: Severe Group A Streptococcus Infections in Paris, France, 2018-2023 acronym: IGASI overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-06 date: 2024-06 date: 2024-03-07 date: 2024-03-12 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: Streptococcus pyogenes, commonly referred to as Group A Streptococcus (GAS), has the ability to induce a diverse range of illnesses.
In several European countries and the United States, a notable surge in invasive GAS (iGAS) infections has been documented since mid-2022. This sharp increase contrasts with the gradual rise in iGAS incidence observed among children over the past three decades. As demonstrated for several viral infections, the recent upturn in iGAS infections is potentially linked to the relaxation of mitigation measures implemented during the COVID-19 pandemic, such as face mask usage and school closures.
Since November 2022, concerns have been raised by French public health authorities regarding the rise in levels of iGAS infections, and an unexpected increase in pediatric severe GAS infections was reported in a French single-center study. However, this study ended in December 2022 and could only explore short-term trends. The Necker - Enfants malades Hospital in Paris, France, represents an excellent opportunity to examine the impact of the COVID-19 pandemic and the associated non-pharmaceutical interventions on the incidence of severe GAS infections, during, and after the pandemic.
This study aims to investigate trends of severe GAS infection incidence in children in the Paris area over the course of the COVID-19 pandemic. conditions: Invasive Group A Beta-Haemolytic Streptococcal Disease studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 300 type: ESTIMATED name: Collection of data from the patient's medical file measure: Monthly incidence of severe Group A Streptococcus (GAS) infections per 1000 pediatric hospital admissions measure: Age of children age with group A Streptococcus (GAS) infections measure: Proportion of children needing surgical intervention for the management of GAS infection measure: Proportion of cases admitted in the PICU for GAS infection measure: Proportion of deaths from GAS infection measure: Hospital length of stay for the management of GAS infection measure: Distribution of infection type of GAS infection measure: Proportion of healthcare-associated infections during the management of GAS infection sex: ALL maximumAge: 17 Years stdAges: CHILD facility: Hôpital Necker-Enfants Malades city: Paris zip: 75015 country: France name: Jérémie Cohen, M.D., PhD role: CONTACT phone: 1 44 49 48 72 phoneExt: +33 email: jeremie.cohen2@aphp.fr lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06297109 id: S-20230033 briefTitle: Maxillary Patient Specific Implants in Bimaxillary Orthognathic Surgery overallStatus: RECRUITING date: 2023-09-12 date: 2027-08-31 date: 2027-08-31 date: 2024-03-07 date: 2024-03-07 name: Hospital of South West Jutland class: OTHER name: University of Southern Denmark briefSummary: Orthognathic surgery is a type of jaw surgery where a surgeon cuts the bones of the upper and lower jaw and places them better. There are two ways they can put the bones in the correct place and keep them in place after the surgery. One way, called the "conventional method", is to use a 3D-printed guide called a splint to set the bones in the right place and then screw the bones together using metal plates that the surgeon bends into shape to fit during the surgery. Another way is to use a patient-specific implants (PSI) that has been 3D-printed in titanium beforehand that because of its unique shape both places and keeps all the bones in the correct place after they are screwed in. Both ways of doing it are golden standards, meaning they are already approved.